Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.5680
-0.0009 (-0.16%)
At close: Feb 4, 2026, 4:00 PM EST
0.6411
+0.0731 (12.87%)
Pre-market: Feb 5, 2026, 5:48 AM EST
Nexalin Technology Revenue
Nexalin Technology had revenue of $18.15K in the quarter ending September 30, 2025, a decrease of -49.63%. This brings the company's revenue in the last twelve months to $156.93K, down -3.18% year-over-year. In the year 2024, Nexalin Technology had annual revenue of $168.72K with 52.35% growth.
Revenue (ttm)
$156.93K
Revenue Growth
-3.18%
P/S Ratio
52.43
Revenue / Employee
$26,155
Employees
6
Market Cap
10.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 168.72K | 57.97K | 52.35% |
| Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
| Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
| Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
| Dec 31, 2020 | 242.91K | 35.53K | 17.13% |
| Dec 31, 2019 | 207.38K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Trinity Biotech | 48.57M |
| Lifeward | 24.50M |
| Beyond Air | 5.80M |
| Intelligent Bio Solutions | 3.29M |
| Tenon Medical | 3.23M |
| Sintx Technologies | 1.27M |
| Movano | 500.00K |
| iTonic Holdings | 305.22K |
NXL News
- 2 days ago - Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation - GlobeNewsWire
- 21 days ago - Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD - GlobeNewsWire
- 2 months ago - Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program - GlobeNewsWire
- 2 months ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4 - GlobeNewsWire
- 2 months ago - Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity - GlobeNewsWire
- 2 months ago - Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel - GlobeNewsWire
- 3 months ago - Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia - GlobeNewsWire
- 3 months ago - Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel - GlobeNewsWire